Hyperfine Secures FDA Clearance For Next-Gen AI-Powered Portable MRI Scanner

0.00% Pre

Hyperfine Inc Ordinary Shares - Class A

HYPR

0.00

This major Swoop® system scanner redesign and Optive AI™ software elevate the AI-powered portable MRI experience for clinicians and their patients across multiple sites of care.

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—announced today FDA clearance of its most significant technological advancement to date. Theclearance includes an entirely new portable MRI scanner powered by the proprietary Optive AI™software. This new system delivers the highest level of image quality, functionality, and usability to date, unlocking a new brain imaging paradigm for clinicians and their patients.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Profusa CEO Says 'Co To Capitalize On The Near-Term European And U.S. Lumee Oxygen Opportunity To Deliver 2026 Potential Revenue Of $500K To $2M And $9M To $13M Potential Revenue In 2027

Stock Ratings | With upside potential of 565.02%, Wells Fargo maintains its "Overweight" rating on Annexon (ANNX) and raises its price target from $14 to $27.

Nano X Imaging Q3 EPS $(0.15) Beats $(0.17) Estimate

Dow Jumps 600 Points; US Adds 119,000 Jobs In September

Insulet Announces 2025–2028 Financial Outlook; Sees Revenue Projected To Grow At A CAGR Of ~20% At Constant Currency Rates, Driven By Continued Omnipod Adoption And Geographic Expansion; Adjusted Operating Margin Expected To Expand Annually By ~10...

UPDATE 1-GE Healthcare to acquire Intelerad for $2.3 billion

UPDATE 2-GE HealthCare to buy Intelerad for $2.3 billion to expand in outpatient care market

This Insider Has Just Sold Shares In Avanos Medical